Yaoming biological opened its first overseas biopharmaceutical production base in Ireland

December 5, 2018 / Meitong news agency / -- the world's leading open biopharmaceutical technology platform company, wuxibiology (2269 HK), announced on December 5 that it would officially open a biopharmaceutical production base in Dundalk, Ireland This is the first production base invested and constructed by Yaoming bio outside China, and also the leading large-scale overseas construction and new plant investment project in China's pharmaceutical industry With the full support of the Irish government and Ida, the base will continue to apply the leading one-time biological reaction technology, adopt the traditional flow processing or perfusion production technology, and carry out the commercial production with the advanced "new generation of biological pharmaceutical production technology" (continuous production technology), which is expected to become the world's leading "future plant" of biopharmaceuticals 。 A total of 48000 liters of flow plus cell culture reactor and 6000 liters of perfusion process bioreactor are newly installed in the base, which is expected to become one of the largest biopharmaceutical bases using disposable bioreactor in the world Dr Chen Zhisheng, CEO of YaoMing bio, said: "today we are very pleased to witness the official foundation of the first overseas production base of YaoMing bio, which will be the starting point and key link of the international strategic layout of YaoMing bio, to ensure that the highest quality standard of bio pharmaceuticals produced by the company will benefit the global patients through a strong supply chain network We will work with our local partners to build a leading new generation of biopharmaceutical production base in the world and become a showcase for Ireland to build a global Biotechnology Center " As a Hong Kong listed company, Yaoming bio (Stock Code: 02269 HK) is the world's leading open, integrated bio pharmaceutical capability and technology enabling platform The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2018, 187 comprehensive projects have been developed on the platform, including 98 in the preclinical research stage, 78 in the early clinical stage (phase I, phase II), 10 in the late clinical stage (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.